Department of Medicinal Chemistry, University of Kansas, 1251 Wescoe Hall Dr., Lawrence, KS 66045, USA.
ChemMedChem. 2011 Sep 5;6(9):1739-45. doi: 10.1002/cmdc.201100113. Epub 2011 Jul 14.
An alanine scan was performed on the novel κ opioid receptor (KOR) peptide ligand CJ-15,208 to determine which residues contribute to the potent in vivo agonist activity observed for the parent peptide. These cyclic tetrapeptides were synthesized by a combination of solid-phase peptide synthesis of the linear precursors, followed by cyclization in solution. Like the parent peptide, each of the analogues exhibited agonist activity and KOR antagonist activity in an antinociceptive assay in vivo. Unlike the parent peptide, the agonist activity of the potent analogues was mediated predominantly, if not exclusively, by μ opioid receptors (MOR). Thus analogues 2 and 4, in which one of the phenylalanine residues was replaced by alanine, exhibited both potent MOR agonist activity and KOR antagonist activity in vivo. These peptides represent novel lead compounds for the development of peptide-based opioid analgesics.
对新型 κ 阿片受体 (KOR) 肽配体 CJ-15,208 进行丙氨酸扫描,以确定哪些残基有助于观察到母体肽的强体内激动剂活性。这些环状四肽通过线性前体的固相肽合成与溶液中环化相结合来合成。与母体肽一样,每种类似物在体内抗伤害性测定中均表现出激动剂活性和 KOR 拮抗剂活性。与母体肽不同的是,强效类似物的激动剂活性主要(如果不是完全)由 μ 阿片受体 (MOR) 介导。因此,类似物 2 和 4 中,一个苯丙氨酸残基被丙氨酸取代,在体内同时表现出强 MOR 激动剂活性和 KOR 拮抗剂活性。这些肽代表了基于肽的阿片类镇痛药开发的新型先导化合物。